Loxo Oncology (LOXO) Given Media Sentiment Score of 0.19

Media stories about Loxo Oncology (NASDAQ:LOXO) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Loxo Oncology earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.4122197042238 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have effected Accern Sentiment’s rankings:

Loxo Oncology (NASDAQ LOXO) opened at $87.79 on Friday.

Loxo Oncology (NASDAQ:LOXO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.15). During the same quarter in the previous year, the business earned ($0.77) earnings per share. equities research analysts expect that Loxo Oncology will post -4.33 EPS for the current year.

A number of research firms have issued reports on LOXO. BTIG Research reaffirmed a “buy” rating and issued a $102.00 price target (up previously from $75.00) on shares of Loxo Oncology in a report on Friday, September 29th. Cowen and Company reaffirmed a “buy” rating on shares of Loxo Oncology in a report on Thursday, September 28th. Morgan Stanley reaffirmed an “overweight” rating and issued a $103.00 price target (up previously from $95.00) on shares of Loxo Oncology in a report on Friday, October 6th. Citigroup Inc reaffirmed a “buy” rating and issued a $112.00 price target (up previously from $86.00) on shares of Loxo Oncology in a report on Friday, October 20th. Finally, JMP Securities cut shares of Loxo Oncology from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $83.12 to $17.14 in a report on Tuesday, August 29th. They noted that the move was a valuation call. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $80.02.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.com-unik.info/2017/11/04/loxo-oncology-loxo-given-media-sentiment-score-of-0-19.html.

In other news, CEO Joshua H. Bilenker sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, October 31st. The stock was sold at an average price of $86.49, for a total transaction of $648,675.00. Following the sale, the chief executive officer now owns 196,207 shares of the company’s stock, valued at $16,969,943.43. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Naarden Jacob Van sold 3,082 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $73.57, for a total value of $226,742.74. Following the sale, the insider now directly owns 1,541 shares in the company, valued at approximately $113,371.37. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 100,637 shares of company stock worth $8,245,787. 44.40% of the stock is currently owned by insiders.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

What are top analysts saying about Loxo Oncology Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Loxo Oncology Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit